Infection with hepatitis B virus (HBV) can resolve without treatment, but 257 million people around the world are affected by chronic hepatitis B virus. Chronic hepatitis B infection requires regular monitoring and increases risk of developing cirrhosis or liver cancer.
Hepatitis D virus (HDV) leads to the most severe form of viral hepatitis. You can only get HDV if you also have HBV, and HDV can lead to more severe liver disease than HBV infection alone. For the 20 million people infected with HDV worldwide, there is no approved therapy to treat HDV. We are working on phase II and III studies of investigational therapies for hepatitis B and hepatitis D infection.
To learn more about these studies call 323-954-0400 or fill out the form below and we’ll get back to you.
Ruane Clinical Research is a dedicated and diverse team of physicians and allied health professionals with expertise in the treatment of HIV, hepatitis B, hepatitis C, Nonalcoholic Steatohepatitis (NASH) and HIV prevention (PrEP). Studying the newest therapies available from the leading international bio-pharmaceutical companies, we have conducted 176 clinical trials since 2006.
Dr. Peter Ruane is a board-certified Infectious Disease and Internal Medicine physician. Dr. Ruane first engaged in clinical research in 1995 at the height of the AIDS crisis with the advent of protease inhibitor therapy. He has since been a principal investigator for every HIV drug marketed since 1997. He has witnessed the importance of bringing new therapies expeditiously to patients.